JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB191944

Recombinant Human CD229 protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human CD229 protein is a Human Fragment protein, in the 48 to 454 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, HPLC.

View Alternative Names

CD229, CDABP0070, LY9, T-lymphocyte surface antigen Ly-9, Cell surface molecule Ly-9, Lymphocyte antigen 9, SLAM family member 3, Signaling lymphocytic activation molecule 3, SLAMF3

Key facts

Purity

>95% SDS-PAGE

Endotoxin level

< 1 EU/µg

Expression system

HEK 293 cells

Tags

His tag C-Terminus

Applications

HPLC, SDS-PAGE

applications

Biologically active

No

Accession

Q9HBG7

Animal free

No

Carrier free

No

Species

Human

Reconstitution

Reconstitute at 100 µg/mL in PBS

Storage buffer

pH: 7.4 Constituents: 100% PBS

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "HPLC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

You may be interested in:

AB277431

Human CD229 ELISA Kit

0

0 Reviews

View product

We recommend this product because it’s often used in the same experiment or related research.

We advise that you always check the datasheet to ensure it fits your experiments, or contact ourtechnical teamfor help.

Sequence info

[{"sequence":"KDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFARPKENVTIMVKSYLGRLDITKWSYSLCISNLTLNDAGSYKAQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSVKGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQRSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKVVWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIEDAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRISLTCSVEDGGNTVMYTWTPLQKEAVVSQGESHLNVSWRSSENHPNLTCTASNPVSRSSHQFLSENICSGPERNTK","proteinLength":"Fragment","predictedMolecularWeight":"39.12 kDa","actualMolecularWeight":null,"aminoAcidEnd":454,"aminoAcidStart":48,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q9HBG7","tags":[{"tag":"His","terminus":"C-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
A few weeks
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD229 also known as SLAMF3 or Ly9 is a transmembrane protein that weighs approximately 80 kDa. This protein belongs to the CD2 subset of the immunoglobulin superfamily. You can find high expression of CD229 in various lymphoid tissues such as the spleen thymus and peripheral blood lymphocytes. Its expression is notably high in T cells B cells and natural killer (NK) cells. As a homophilic receptor CD229 aids in cell-cell adhesion playing an essential role in immune response regulation among lymphocytes.
Biological function summary

CD229 influences signaling within immune cells. It functions as a mediator of adhesion and activation signaling pathways. CD229 does not act alone and often works as part of a receptor complex that may include CD48 and other members of the SLAM family. Besides its role in cellular adhesion CD229 participates in balancing immune activation and immune tolerance demonstrating its importance in developing and maintaining a robust immune response.

Pathways

CD229 participates in the adaptive immune signaling pathways. It links with other signaling proteins such as SAP (SLAM-associated protein) a critical modulator of downstream signaling cascades. SAP interacts with SLAM-family receptors including CD229 to regulate T and B cell activation and function. The involvement of CD229 in various immune signaling pathways positions it as a significant player in the broader context of cellular communication and response within the immune system.

CD229's aberrant expression or dysfunction links to autoimmune diseases such as systemic lupus erythematosus (SLE) and certain hematological malignancies. Altered CD229 expression has been observed in association with SLE where it may contribute to dysregulated immune responses. In hematological cancers CD229 overexpression or mutations can disrupt immune cell regulation promoting tumor progression. CD229 may interact with other SLAM-family proteins like CD244 which have implications in disease pathology and can be targets for therapeutic interventions.

Specifications

Form

Lyophilized

Additional notes

Purity greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE.

General info

Function

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed : 22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed : 22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed : 22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed : 22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity).
See full target information LY9

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Associated Products

Select an associated product type
Alternative Product
Proteins & Peptides

AB243790

Recombinant human TACI protein (Active)

proteins-peptides

recombinant-human-taci-protein-active-ab243790

0

(0 reviews)

Alternative Product
Proteins & Peptides

AB140539

Recombinant Human TACI protein (denatured)

proteins-peptides

recombinant-human-taci-protein-denatured-ab140539

0

(0 reviews)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com